Literature DB >> 28638976

LILRB receptor-mediated regulation of myeloid cell maturation and function.

William van der Touw1, Hui-Ming Chen1,2, Ping-Ying Pan1,2, Shu-Hsia Chen3,4.   

Abstract

The leukocyte immunoglobulin-like receptor (LILR) family comprises a set of paired immunomodulatory receptors expressed among human myeloid and lymphocyte cell populations. While six members of LILR subfamily A (LILRA) associate with membrane adaptors to signal via immunoreceptor tyrosine-based activating motifs (ITAM), LILR subfamily B (LILRB) members signal via multiple cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIM). Ligand specificity of some LILR family members has been studied in detail, but new perspective into the immunoregulatory aspects of this receptor family in human myeloid cells has been limited. LILRB receptors and the murine ortholog, paired immunoglobulin-like receptor B (PIRB), have been shown to negatively regulate maturation pathways in myeloid cells including mast cells, neutrophils, dendritic cells, as well as B cells. Our laboratory further demonstrated in mouse models that PIRB regulated functional development of myeloid-derived suppressor cell and the formation of a tumor-permissive microenvironment. Based on observations from the literature and our own studies, our laboratory is focusing on how LILRs modulate immune homeostasis of human myeloid cells and how these pathways may be targeted in disease states. Integrity of this pathway in tumor microenvironments, for example, permits a myeloid phenotype that suppresses antitumor adaptive immunity. This review presents the evidence supporting a role of LILRs as myeloid cell regulators and ongoing efforts to understand the functional immunology surrounding this family.

Entities:  

Keywords:  ITIM; LILRA; LILRB; Macrophage; Regulatory myeloid suppressor cells; SHP

Mesh:

Substances:

Year:  2017        PMID: 28638976      PMCID: PMC5591173          DOI: 10.1007/s00262-017-2023-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  85 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  Induction of antigen-specific human T suppressor cells by membrane and soluble ILT3.

Authors:  George Vlad; Nicole Suciu-Foca
Journal:  Exp Mol Pathol       Date:  2012-09-24       Impact factor: 3.362

3.  Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis.

Authors:  Ariel Munitz; Eric T Cole; Amanda Beichler; Katherine Groschwitz; Richard Ahrens; Kris Steinbrecher; Tara Willson; Xiaonan Han; Lee Denson; Marc E Rothenberg; Simon P Hogan
Journal:  Gastroenterology       Date:  2010-04-14       Impact factor: 22.682

4.  Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas.

Authors:  Xing Fan; Yinyan Wang; Chuanbao Zhang; Xing Liu; Zenghui Qian; Tao Jiang
Journal:  J Neuroimmunol       Date:  2016-03-28       Impact factor: 3.478

5.  The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells.

Authors:  Neil T Young; Edward C P Waller; Rashmi Patel; Ali Roghanian; Jonathan M Austyn; John Trowsdale
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

6.  Novel HLA-G-binding leukocyte immunoglobulin-like receptor (LILR) expression patterns in human placentas and umbilical cords.

Authors:  R H McIntire; T Sifers; J S Platt; K G Ganacias; D K Langat; J S Hunt
Journal:  Placenta       Date:  2008-06-05       Impact factor: 3.481

7.  Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals.

Authors:  George Vlad; Flavia Piazza; Adriana Colovai; Raffaello Cortesini; Fatima Della Pietra; Nicole Suciu-Foca; John S Manavalan
Journal:  Hum Immunol       Date:  2003-05       Impact factor: 2.850

8.  Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development.

Authors:  Yu Mori; Sukenao Tsuji; Masanori Inui; Yuzuru Sakamoto; Shota Endo; Yumi Ito; Shion Fujimura; Takako Koga; Akira Nakamura; Hiroshi Takayanagi; Eiji Itoi; Toshiyuki Takai
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

9.  The Leukocyte Immunoglobulin-Like Receptor Family Member LILRB5 Binds to HLA-Class I Heavy Chains.

Authors:  Zhiyong Zhang; Hiroko Hatano; Jacqueline Shaw; Marloes Olde Nordkamp; Guosheng Jiang; Demin Li; Simon Kollnberger
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

10.  ANGPTL2/LILRB2 signaling promotes the propagation of lung cancer cells.

Authors:  Xiaoye Liu; Xiaoting Yu; Jingjing Xie; Mengna Zhan; Zhuo Yu; Li Xie; Hongxiang Zeng; Feifei Zhang; Guoqiang Chen; Xianghua Yi; Junke Zheng
Journal:  Oncotarget       Date:  2015-08-28
View more
  36 in total

1.  Analysis of the immune response to sciatic nerve injury identifies efferocytosis as a key mechanism of nerve debridement.

Authors:  Ashley L Kalinski; Choya Yoon; Lucas D Huffman; Patrick C Duncker; Rafi Kohen; Ryan Passino; Hannah Hafner; Craig Johnson; Riki Kawaguchi; Kevin S Carbajal; Juan Sebastian Jara; Edmund Hollis; Daniel H Geschwind; Benjamin M Segal; Roman J Giger
Journal:  Elife       Date:  2020-12-02       Impact factor: 8.140

2.  Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.

Authors:  William van der Touw; Kyeongah Kang; Yi Luan; Ge Ma; Sunny Mai; Lihui Qin; Guanglin Bian; Ruihua Zhang; Sathish Kumar Mungamuri; Hong-Ming Hu; Cheng Cheng Zhang; Stuart A Aaronson; Marc Feldmann; Wen-Chin Yang; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

Review 3.  Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Authors:  Dana L Casey; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2020-02       Impact factor: 11.151

Review 4.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

5.  Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.

Authors:  Xun Gui; Mi Deng; Hao Song; Yuanzhi Chen; Jingjing Xie; Zunling Li; Licai He; Fangfang Huang; Yixiang Xu; Yasuaki Anami; Hai Yu; Chenyi Yu; Leike Li; Zihao Yuan; Xiaoying Xu; Qihui Wang; Yan Chai; Tao Huang; Yi Shi; Kyoji Tsuchikama; X Charlene Liao; Ningshao Xia; George F Gao; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An
Journal:  Cancer Immunol Res       Date:  2019-06-18       Impact factor: 11.151

Review 6.  Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission.

Authors:  Mariola Kurowska-Stolarska; Stefano Alivernini
Journal:  Nat Rev Rheumatol       Date:  2022-06-07       Impact factor: 32.286

7.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

Review 8.  Phagocytosis checkpoints as new targets for cancer immunotherapy.

Authors:  Mingye Feng; Wen Jiang; Betty Y S Kim; Cheng Cheng Zhang; Yang-Xin Fu; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2019-08-28       Impact factor: 60.716

Review 9.  Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.

Authors:  Kyohei Nakamura; Mark J Smyth
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

Review 10.  Innate allorecognition in transplantation.

Authors:  Khodor I Abou-Daya; Martin H Oberbarnscheidt
Journal:  J Heart Lung Transplant       Date:  2021-03-29       Impact factor: 13.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.